| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 81, 3650-3653, Copyright © 1996 by Endocrine Society
ARTICLES |
KB Ain, S Tofiq and KD Taylor
Department of Internal Medicine, Veterans Administration Medical Center, Lexington, Kentucky, USA.
Anaplastic thyroid carcinoma is a rapidly fatal neoplasm that fails to adequately respond to any known chemotherapeutic regimen. We tested taxol (paclitaxel) against six human anaplastic thyroid carcinoma cell lines (DRO-90, ARO-81, KAT-4, KAT-18, SW-1736, and BHT-101). Each cell line monolayer culture, in log phase growth, was treated with taxol concentrations ranging from 0.001-5.0 mumol/L. Cell numbers, after 24-, 48-, and 72-h growth periods in separate experiments, were expressed as percentages of control cell numbers without taxol. All cell lines showed maximal inhibition with 0.05 mumol/L taxol at 3-28% of control cell numbers. Greater inhibition was seen with longer growth periods. Three cell lines (DRO-90, ARO-81, and KAT-4) were grown as sc xenograft tumors in nude mice for 18-26 days. Treatment groups received sc taxol injections in sites distant from the tumors, whereas control mice received vehicle. All taxol-treated xenografts were inhibited to near- starting volume or disappeared, whereas control xenograft volumes increased 9- to 59-fold. These results suggest that taxol may have beneficial clinical effects in anaplastic thyroid carcinoma patients.
This article has been cited by other articles:
 |
|
 |
|
  O. Ericsson, J. Jarvius, E. Schallmeiner, M. Howell, R. Y. Nong, H. Reuter, M. Hahn, J. Stenberg, M. Nilsson, and U. Landegren A dual-tag microarray platform for high-performance nucleic acid and protein analyses Nucleic Acids Res., May 1, 2008; 36(8): e45 - e45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salvatore, T. C. Nappi, P. Salerno, Y. Jiang, C. Garbi, C. Ugolini, P. Miccoli, F. Basolo, M. D. Castellone, A. M. Cirafici, et al. A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma Cancer Res., November 1, 2007; 67(21): 10148 - 10158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. J. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin Combination Chemotherapy Including Combretastatin A4 Phosphate and Paclitaxel Is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2902 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brignardello, M. Gallo, I. Baldi, N. Palestini, A. Piovesan, E. Grossi, G. Ciccone, and G. Boccuzzi Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years Eur. J. Endocrinol., April 1, 2007; 156(4): 425 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Kogai, K Taki, and G A Brent Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salvatore, V. De Falco, P. Salerno, T. C. Nappi, S. Pepe, G. Troncone, F. Carlomagno, R. M. Melillo, S. M. Wilhelm, and M. Santoro BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma Clin. Cancer Res., March 1, 2006; 12(5): 1623 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Younes, S. Kim, O. G. Yigitbasi, M. Mandal, S. A. Jasser, Y. Dakak Yazici, B. A. Schiff, A. El-Naggar, B. N. Bekele, G. B. Mills, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer Mol. Cancer Ther., August 1, 2005; 4(8): 1146 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pan, H. Huang, L. Sun, B. Fang, and S.-C. J. Yeung Bcl-2-Associated X Protein Is the Main Mediator of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3583 - 3591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pan, M. She, Z.-X. Xu, L. Sun, and S.-C. J. Yeung Farnesyltransferase Inhibitors Induce DNA Damage via Reactive Oxygen Species in Human Cancer Cells Cancer Res., May 1, 2005; 65(9): 3671 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cozzolino, P. Palladino, F. Rossi, G. Cali, E. Benedetti, and P. Laccetti Antineoplastic cyclic astin analogues kill tumour cells via caspase-mediated induction of apoptosis Carcinogenesis, April 1, 2005; 26(4): 733 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Klopper, W. R. Hays, V. Sharma, M. A. Baumbusch, J. M. Hershman, and B. R. Haugen Retinoid X receptor-{gamma} and peroxisome proliferator-activated receptor-{gamma} expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment Mol. Cancer Ther., August 1, 2004; 3(8): 1011 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Pushkarev, D. V. Starenki, V. A. Saenko, H. Namba, J. Kurebayashi, M. D. Tronko, and S. Yamashita Molecular Mechanisms of the Effects of Low Concentrations of Taxol in Anaplastic Thyroid Cancer Cells Endocrinology, July 1, 2004; 145(7): 3143 - 3152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Dziba and K. B. Ain Imatinib Mesylate (Gleevec; STI571) Monotherapy Is Ineffective in Suppressing Human Anaplastic Thyroid Carcinoma Cell Growth in Vitro J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2127 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xu, R. M. Quiros, J. B. Maxhimer, P. Jiang, R. Marcinek, K. B. Ain, J. L. Platt, J. Shen, P. Gattuso, and R. A. Prinz Inverse Correlation between Heparan Sulfate Composition and Heparanase-1 Gene Expression in Thyroid Papillary Carcinomas: A Potential Role in Tumor Metastasis Clin. Cancer Res., December 1, 2003; 9(16): 5968 - 5979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Nikiforova, E. T. Kimura, M. Gandhi, P. W. Biddinger, J. A. Knauf, F. Basolo, Z. Zhu, R. Giannini, G. Salvatore, A. Fusco, et al. BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5399 - 5404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Portella, R. Pacelli, S. Libertini, L. Cella, G. Vecchio, M. Salvatore, and A. Fusco ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 5027 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pietras, M. Stumm, M. Hubert, E. Buchdunger, K. Rubin, C.-H. Heldin, P. McSheehy, M. Wartmann, and A. Ostman STI571 Enhances the Therapeutic Index of Epothilone B by a Tumor-selective Increase of Drug Uptake Clin. Cancer Res., September 1, 2003; 9(10): 3779 - 3787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Spalletti-Cernia, R. Sorrentino, S. Di Gaetano, A. Arciello, C. Garbi, R. Piccoli, G. D'Alessio, G. Vecchio, P. Laccetti, and M. Santoro Antineoplastic Ribonucleases Selectively Kill Thyroid Carcinoma Cells Via Caspase-Mediated Induction of Apoptosis J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2900 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Yang, J.-X. Pan, L. Sun, and S.-C. J. Yeung p21 Waf-1 (Cip-1) Enhances Apoptosis Induced by Manumycin and Paclitaxel in Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 763 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Pietras, K. Rubin, T. Sjoblom, E. Buchdunger, M. Sjoquist, C.-H. Heldin, and A. Ostman Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy Cancer Res., October 1, 2002; 62(19): 5476 - 5484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Portella, S. Scala, D. Vitagliano, G. Vecchio, and A. Fusco ONYX-015, an E1B Gene-Defective Adenovirus, Induces Cell Death in Human Anaplastic Thyroid Carcinoma Cell Lines J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2525 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Pan, G. Xu, and S.-C. J. Yeung Cytochrome c Release Is Upstream to Activation of Caspase-9, Caspase-8, and Caspase-3 in the Enhanced Apoptosis of Anaplastic Thyroid Cancer Cells Induced by Manumycin and Paclitaxel J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4731 - 4740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kitazono, R. Robey, Z. Zhan, N. J. Sarlis, M. C. Skarulis, T. Aikou, S. Bates, and T. Fojo Low Concentrations of the Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Increase Expression of the Na+/I- Symporter and Iodine Accumulation in Poorly Differentiated Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3430 - 3435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Xu, J. Pan, C. Martin, and S.-C. J. Yeung Angiogenesis Inhibition in the in Vivo Antineoplastic Effect of Manumycin and Paclitaxel against Anaplastic Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1769 - 1777. [Abstract] [Full Text]
|
|
|
|
|
|
M. Kitazono, Y. Chuman, T. Aikou, and T. Fojo Construction of Gene Therapy Vectors Targeting Thyroid Cells: Enhancement of Activity and Specificity with Histone Deacetylase Inhibitors and Agents Modulating the Cyclic Adenosine 3',5'-Monophosphate Pathway and Demonstration of Activity in Follicular and Anaplastic Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 834 - 840. [Abstract] [Full Text]
|
|
|
|
|
|
S.-C. J. Yeung, G. Xu, J. Pan, M. Christgen, and A. Bamiagis Manumycin Enhances the Cytotoxic Effect of Paclitaxel on Anaplastic Thyroid Carcinoma Cells Cancer Res., February 1, 2000; 60(3): 650 - 656. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
